Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Perioperative durvalumab plus FLOT led to significantly better event-free survival outcomes than FLOT alone among participants with resectable gastric or gastroesophageal junction adenocarcinoma. (Funded by AstraZeneca; MATTERHORN ClinicalTrials.gov number, NCT04592913.).

Bookmark

Cite This Study

Janjigian et al. (Sun,) studied this question.

synapsesocial.com/papers/69d8f89d1ab91f1400bede63 https://doi.org/https://doi.org/10.1056/nejmoa2503701

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.2023 · 41 citations
2LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG2024 · 2 citations
3Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024 · 22,881 citations
4First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial2021 · 2,915 citations
5The patterns and timing of recurrence after curative resection for gastric cancer in China2016 · 130 citations

Bookmark